Mismatch repair/microsatellite instability (MMR/MSI) testing practices among United States physicians treating patients (pts) with advanced/metastatic colorectal cancer (mCRC).

被引：0
|
作者：
Eriksson, Jennifer
Amonkar, Mayur
Thomson, Gemma
Lambert, Jeremy
Malmenas, Mia
Chase, Monica
Sun, Lucy
Kollmar, Linda Grossman
Vichnin, Michelle
机构：
[1] ICON Plc, Commercialisat & Outcomes, Stockholm, Sweden
[2] Merck & Co Inc, N Wales, PA USA
[3] ICON Plc, London, England
[4] Mapi, Lyon, France
[5] ICON Plc, Stockholm, Sweden
[6] ICON Plc, Commercialisat & Outcomes, Boston, MA USA
[7] Merck & Co Inc, Kenilworth, NJ USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2019年 / 37卷 / 04期
关键词：
D O I：
10.1200/JCO.2019.37.4_suppl.533
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
533
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Concordance of DNA mismatch repair deficient (dMMR)/microsatellite instability (MSI) assessment by local and central testing in patients with metastatic CRC (mCRC) receiving nivolumab (nivo) in CheckMate 142 study.
    Kopetz, Scott
    Lonardi, Sara
    McDermott, Raymond S.
    Aglietta, Massimo
    Hendlisz, Alain
    Morse, Michael
    Leach, Joseph W.
    Neyns, Bart
    Chan, Emily
    Chen, Franklin
    Wong, Ka Yeung Mark
    Lee, James J.
    Garcia-Alfonso, Pilar
    Hill, Andrew G.
    Lenz, Heinz-Josef
    Desai, Jayesh
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [32] Nivolumab (NIVO) ± ipilimumab (IPI) in patients (pts) with microsatellite instability-high/mismatch repair-deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC): Five-year follow-up from CheckMate 142.
    Overman, Michael J.
    Lenz, Heinz-Josef
    Andre, Thierry
    Aglietta, Massimo
    Wong, Mark Ka
    Luppi, Gabriele
    Van Cutsem, Eric
    McDermott, Raymond S.
    Hendlisz, Alain
    Cardin, Dana Backlund
    Morse, Michael
    Neyns, Bart
    Hill, Andrew Graham
    Limon, M. Luisa
    Garcia-Alfonso, Pilar
    Krishnamurthy, Anuradha
    Chen, Franklin
    Abdullaev, Sandzhar
    Soleymani, Samira
    Lonardi, Sara
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [33] Clinical outcomes in patients with microsatellite instability-high (MSI-H) metastatic colorectal cancer (mCRC) in the pre-immunotherapy era.
    Zwart, Koen
    van der Baan, Frederieke
    Dixon, Matthew
    Frantz, Bryan
    Punt, Cornelis J. A.
    Koopman, Miriam
    Vink, Geraldine R.
    Roodhart, Jeanine
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : 65 - 65
  • [34] SAFETY PROFILE OF NIVOLUMAB plus IPILIMUMAB COMBINATION THERAPY IN PATIENTS WITH DNA MISMATCH REPAIR-DEFICIENT/MICROSATELLITE INSTABILITY-HIGH (DMMR/MSI-H) METASTATIC COLORECTAL CANCER (MCRC) IN CHECKMATE-142
    Brutcher, Edith
    Khoukaz, Taline
    Hartman, Leighanne
    ONCOLOGY NURSING FORUM, 2018, 45 (02)
  • [35] COMPARISON OF REAL-WORLD LATER-LINE TREATMENT OUTCOMES IN PATIENTS WITH MICROSATELLITE-INSTABILITY HIGH (MSI-H) VERSUS MICROSATELLITE-STABLE (MSS) METASTATIC COLORECTAL CANCER (MCRC) IN THE UNITED STATES (US)
    Dixon, M.
    Gu, J.
    VALUE IN HEALTH, 2022, 25 (07) : S313 - S314
  • [36] Genomic Profiling for KRAS, NRAS, BRAF, Microsatellite Instability, and Mismatch Repair Deficiency Among Patients With Metastatic Colon Cancer
    Gutierrez, Martin E.
    Price, Kristin S.
    Lanman, Richard B.
    Nagy, Rebecca J.
    Shah, Irfan
    Mathura, Shivam
    Mulcahy, Michael
    Norden, Andrew D.
    Goldberg, Stuart L.
    JCO PRECISION ONCOLOGY, 2019, 3 : 1 - 9
  • [37] Nivolumab (NIVO) plus low-dose ipilimumab (IPI) in previously treated patients (pts) with microsatellite instability-high/mismatch repair-deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC): Long-term follow-up.
    Overman, Michael J.
    Lonardi, Sara
    Wong, Ka Yeung Mark
    Lenz, Heinz-Josef
    Gelsomino, Fabio
    Aglietta, Massimo
    Morse, Michael
    Van Cutsem, Eric
    McDermott, Raymond S.
    Hill, Andrew G.
    Sawyer, Michael B.
    Hendlisz, Alain
    Neyns, Bart
    Svrcek, Magali
    Atasoy, Ajlan
    Zhao, Huanyu
    Lei, Ming
    Kopetz, Scott
    Andre, Thierry
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (04)
  • [38] One-year duration of nivolumab plus ipilimumab in patients (pts) with microsatellite instability-high/mismatch repair-deficient (MSI/dMMR) metastatic colorectal cancer (mCRC): Long-term follow-up of the GERCOR NIPICOL phase II study
    Cohen, Romain
    Meurisse, Aurelia
    Pudlarz, Thomas
    Bennouna, Jaafar
    Tournigand, Christophe
    De La Fouchardiere, Christelle
    Tougeron, David
    Borg, Christophe
    Mazard, Thibault
    Chibaudel, Benoist
    Garcia-Larnicol, Marie-Line
    Svrcek, Magali
    Menu, Yves
    Vernerey, Dewi
    Andre, Thierry
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (04)
  • [39] Retrospective review of endometrial cancer (EC) specimens in individuals younger than age 50 for microsatellite instability (MSI) testing and DNA mismatch repair enzyme (MMR) expression.
    Nugent, W.
    Durie, N.
    Palaia, T.
    Ragolia, L.
    Hanna, I.
    Staszewski, H.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [40] Exploratory analysis of baseline microsatellite instability (MSI) status in patients with metastatic colorectal cancer (mCRC) treated with regorafenib (REG) or placebo in the phase 3 CORRECT trial
    Koechert, K.
    Beckmann, G.
    Teufel, M.
    ANNALS OF ONCOLOGY, 2017, 28
12345